Ferrara Pietro, Sannicandro Valeria, Ianniello Francesca, Quattrocchi Enrica, Sbordone Annamaria, Petitti Tommasangelo, Mariotti Paolo
Institute of Pediatrics, Catholic University Medical School, Rome, Italy -
Service of Pediatrics, Campus Bio-Medico University, Rome, Italy -
Minerva Pediatr. 2019 Apr;71(2):135-138. doi: 10.23736/S0026-4946.17.04680-1. Epub 2017 Mar 3.
The aim of this study was to evaluate the effectiveness of treatment with methylphenidate or desmopressin (dDAVP) in patients with comorbid attention-deficit/hyperactivity disorder (ADHD) and enuresis.
We enrolled 103 patients affected by ADHD and 125 patients with monosymptomatic nocturnal enuresis (NE). Data were collected between January 2014 and December 2015. The study was carried out in compliance with the Helsinki Declaration.
About children with ADHD, 9/103 (8.7%) were also suffering from NE; of those 8/9 followed treatment with methylphenidate and cognitive behavioral therapy. After 3 months 2/8 (25%, CI 95%: 8-65%) showed improvements, remaining 75% has been increased dosage of methylphenidate. After 6 months a response was achieved in 6/8 (75%, CI 95%: 35-96%) children and 1/8 was lost to follow-up. Furthermore the drug withdrawal showed a recurrence of symptoms both ADHD and NE in 1/7 (14.3%, CI 95%: 0.3-57%) vs. 6/7 (85.7%, CI 95%: 42-99%) that not presented recurrences. About children with NE enrolled at Campus Bio-Medico University it was found that 4/125 (3.8%) children were also suffering from ADHD; 3/4 (75%) treated with dDAVP and motivational therapy, of those 2/3 (66.7%, CI 95%: 9-99%) showed no improvements of symptoms vs. 1/3 (33.3%, CI 95%: 0.8-90%) that showed partial response with a reduction of wet-nights.
It is important the service of recruitment of patients with NE. In fact considering NE in a Child Neuropsychiatry Service where patients belong to a diagnosis of ADHD and NE is an incidental finding, this one is not considered as the addressee of treatment, but the therapy is directed to the neuro-behavioral problem using specific drugs and therapies, which are resolutive in the enuretic disorder.
本研究旨在评估哌甲酯或去氨加压素(dDAVP)治疗合并注意缺陷多动障碍(ADHD)和遗尿症患者的有效性。
我们纳入了103例ADHD患者和125例单纯夜间遗尿(NE)患者。数据收集于2014年1月至2015年12月期间。本研究按照《赫尔辛基宣言》开展。
在ADHD患儿中,9/103(8.7%)也患有NE;其中8/9接受了哌甲酯治疗和认知行为疗法。3个月后,2/8(25%,95%CI:8-65%)症状改善,其余75%增加了哌甲酯剂量。6个月后,6/8(75%,95%CI:35-96%)患儿有反应,1/8失访。此外,停药后,1/7(14.3%,95%CI:0.3-57%)的ADHD和NE症状复发,而未复发的为6/7(85.7%,95%CI:-42-99%)。在罗马生物医学大学校园纳入的NE患儿中,发现4/125(3.8%)患儿也患有ADHD;3/4(75%)接受了dDAVP和动机疗法,其中2/3(66.7%,95%CI:9-99%)症状无改善,而1/3(33.3%,95%CI:0.8-90%)有部分反应,尿床次数减少。
NE患者招募服务很重要。事实上,在儿童神经精神病学服务中,若将NE视为ADHD诊断患者的偶然发现,NE不作为治疗对象,而是使用特定药物和疗法针对神经行为问题进行治疗,这些药物和疗法对遗尿症有治疗作用。